「nmda」の共起表現一覧(1語右で並び替え)

nmda

1語右で並び替え

該当件数:97件

  • Its NMDA actions, similar to those of the phenylheptylam
  • NMDA, AMPA kainate, mGluR1, mGluR2, mGluR3, mGluR4,
  • l experiments, Palazzo et al. demonstrated that NMDA, an ionotropic glutamate receptor, and the meta
  • ensory nerve terminals in the skin also express NMDA and non-NMDA receptors.
  • ty of several ion channels including the GABAA, NMDA, and sigma receptors.
  • ors it has been demonstrated to function on are NMDA and the D1 dopamine receptor.
  • ther ionotropic receptors for glutamate such as NMDA and AMPA.
  • It is a non-competitive NMDA antagonist and calcium channel blocker
  • a number of receptor systems, being both a weak NMDA antagonist and a 5HT1A agonist.
  • elucemine (NPS-1506) is a drug which acts as an NMDA antagonist and a serotonin reuptake inhibitor,
  • s a drug related to memantine, which acts as an NMDA antagonist and has neuroprotective effects.
  • as increased glucose metabolism in response to NMDA antagonist exposure.
  • .3x meperidine in potency) although it also has NMDA antagonist properties like its close relative k
  • tive than 18-MC with very little activity as an NMDA antagonist and only slight affinity for the del
  • red in combination with other drugs such as the NMDA antagonist tiletamine or the alpha-2 adrenergic
  • estinel (GV-150,526) is a drug which acts as an NMDA antagonist, binding selectively to the glycine
  • esonprodil (CI-1041) is a drug which acts as an NMDA antagonist, selective for the NR2B subunit.
  • iprodil (SL-82.0715) is a drug which acts as an NMDA antagonist, binding to the polyamine modulatory
  • is a drug developed by Pfizer which acts as an NMDA antagonist, selective for the NR2B subunit.
  • GS-19755) is a drug which acts as a competitive NMDA antagonist, directly competing with glutamate f
  • decahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist.
  • otel (EAA-090) is a drug which acts as a potent NMDA antagonist.
  • -1102) is a drug which acts as a noncompetitive NMDA antagonist.
  • ts and instead acts as a potent non-competitive NMDA antagonist.
  • ome apparent 2 hours after administration of an NMDA antagonist.
  • In animal models, NMDA antagonists increase glutamate release in the p
  • After repeated doses of the NMDA antagonists MK-801 and PCP, the vacuolation rea
  • I added dissociatives ( NMDA antagonists) as psychedelics.
  • MK-801, along with other NMDA antagonists, induce the formation of brain lesi
  • sions") occurred in brains of rats administered NMDA antagonists, including PCP, MK-801 (dizocilpine
  • antidepressant effect when co-administered with NMDA antagonists.
  • oxic changes corresponded with their potency as NMDA antagonists: i.e.
  • NMDA channel has been shown to be involved in long-t
  • Lacosamide does not affect AMPA, kainate, NMDA, GABAA, GABAB or a variety of dopaminergic, ser
  • NMDA receptor
  • (Tet-Gly, LY-285,265) is a potent and selective NMDA receptor agonist, stimulating the NMDA receptor
  • It also acts as an NMDA receptor antagonist.
  • Chemicals that deactivate the NMDA receptor are called antagonists.
  • Most NMDA receptor antagonists are metabolized in the liv
  • Dextrorphan - A dissociative hallucinogen ( NMDA receptor antagonist) and cough suppressant.
  • Frequent administration of most NMDA receptor antagonists can lead to tolerance, whe
  • 2R)-amino-5-phosphonopentanoate) is a selective NMDA receptor antagonist that competitively inhibits
  • esthetic and pharmacologically classified as an NMDA receptor antagonist.
  • and that the cortical NMDA receptor properties and membrane fluidity are a
  • eceptor agonist, κ-opioid receptor agonist, and NMDA receptor antagonist.
  • AP-7 is a selective NMDA receptor (NMDAR) antagonist that competitively
  • It has also been shown to act as a low-affinity NMDA receptor antagonist.
  • Glutamate [ NMDA] receptor subunit 3A is a protein that in human
  • Glutamate [ NMDA] receptor subunit epsilon-1 is a protein that i
  • Glutamate [ NMDA] receptor subunit epsilon-4 is a protein that i
  • stulated that this is a homeostatic response to NMDA receptor blockade, which in turn increases psyc
  • It acts as an NMDA receptor antagonist but has low potency and act
  • CKA (5,7-dichlorokynurenic acid) is a selective NMDA receptor (NMDAR) antagonist acting at the glyci
  • e AMPA receptor antagonist, and non-competitive NMDA receptor antagonist.
  • Glutamate [ NMDA] receptor subunit 3B is a protein that in human
  • development of synaptic elements by modulating NMDA receptor activity.
  • As an NMDA receptor antagonist, in vivo, it is approximate
  • Other NMDA receptor modulators are being studied and this
  • NMDA receptor agonists like ibotenic acid (which is
  • Huperzine A is also a NMDA receptor antagonist which protects the brain ag
  • ing within in vitro preparations, and can block NMDA receptor action at a reasonably small concentra
  • NMDA receptor channels are heteromers composed of th
  • nervous system and has its mode of action as an NMDA receptor antagonist.
  • A class of NMDA receptor antagonists have been denoted dissocia
  • de of GlyT1 has been hypothesized to potentiate NMDA receptor function in vivo and to represent a ra
  • rent ability to stabilize disrupted or disabled NMDA receptor pathways in the brain, which are share
  • trorotary isomer, dextromethorphan, is a common NMDA receptor antagonist and pro-drug to dextrorphan
  • dies of glycine (and related co-agonists at the NMDA receptor) added to conventional anti-psychotics
  • Examples include haemoglobin (pictured), the NMDA receptor, some aquaporins, some AMPA receptors,
  • an receptor site is the PCP binding site in the NMDA receptor, a type of ligand-gated ion channel.
  • The induction of NMDA receptor-dependent long-term potentiation (LTP)
  • apse to an active one, since this conversion is NMDA receptor-dependent.
  • zoline I2 receptor antagonists reversibly block NMDA receptor-mediated Ca2+ influx and thus may inhi
  • PEAQX is a competitive antagonist at the NMDA receptor.
  • -physiological partial agonist of the mammalian NMDA receptor.
  • able AMPA receptor and kainate receptor but not NMDA receptor.
  • ith different subunits of N-methyl-D-aspartate ( NMDA) receptor.
  • antibodies to the delta2 or NR2 subunits of the NMDA receptor.
  • N-methyl-D-aspartate ( NMDA) receptors are a class of ionotropic glutamate
  • d her colleagues demonstrated the importance of NMDA receptors in development plasticity.
  • as a neuronal signaling molecule by activating NMDA receptors in the brain.
  • Glutamate opens NMDA receptors on other neurons which allows calcium
  • NMDA receptors start to become unresponsive, slowing
  • ulators of a variety of ion channels, including NMDA receptors and AMPA receptors.
  • eptor and imidazoline binding sites, and blocks NMDA receptors and other cation ligand-gated channel
  • r treatment focus because glutamate blocks some NMDA receptors which, on their own, induce schizophr
  • ffects on Aplysia long-term potentiation, since NMDA receptors are required for both.
  • encodes a subunit of the N-methyl-D-aspartate ( NMDA) receptors, which belong to the superfamily of
  • neurotrophic factor (BDNF), glutamate acting at NMDA receptors, dopamine through activation of the D
  • ") and ketamine, both of which block glutamate ( NMDA) receptors, are known to cause psychosis closel
  • A and 5-HT2C), 5-HT6, 5-HT7, α1-adrenergic, and NMDA receptors, and as agonists at the sigma recepto
  • ying ovarian or mediastinal teratoma expressing NMDA receptors.
  • ls and has a low affinity for AMPA, kainate and NMDA receptors.
  • t a hypofunction of glutamatergic signaling via NMDA receptors.
  • holine antagonists, with little or no effect on NMDA receptors.
  • ol's acute effects on GABAergic enhancement and NMDA suppression, leading to CNS depression leading
  • kappa and delta opioid, sigma receptors, or the NMDA system are not well understood.